Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Reexamination Certificate
2002-05-09
2010-02-23
Goddard, Laura B (Department: 1642)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
C435S004000, C435S007100, C435S007230
Reexamination Certificate
active
07666393
ABSTRACT:
We have discovered that endothelial progenitor cells (EPC) are particularly suitable for use in a sensitive assay for antiangiogenic factors. We have found that EPC mobilization and differentiation is greatly inhibited by antiangiogenic factors as evidenced in vivo by VEGF inducing a massive mobilization of EPC into the blood circulation which effect is significantly inhibited by endostatin treatment, and, in vitro, human blood-derived EPC forming adherent colonies, which colonies, in the presence of angiogenic factors, give rise to differentiated EC, and which differentiation is disrupted and cell growth is inhibited in the presence of angiostatin and endostatin.
REFERENCES:
patent: 2002/0051762 (2002-05-01), Rafii et al.
Ito et al. (Cancer Research, vol. 59, pp. 5875-5877, 1999, IDS).
Ito et al (Cancer Research, vol. 59, pp. 5875-5877, 1999, IDS).
Takahashi et al (Nat Med, 1999, 5:434-438, IDS).
Asahara et al (Circulation Research, 1999, 85:221-228, IDS).
Isner et al (J Clinical Investigation, 1999, 103:1231-1236, IDS).
Eder et al (“Recombinant Human Endostatin: Results of a Phase I Clinical Trial” Presented in Amsterdam, American Association of Cancer Research, Nov. 7, 2000, IDS).
Ito et al (Cancer Research, vol. 59, pp. 5875-5877, 1999, IDS).
Mancuso et al (Blood, Nov. 2000, 96(11): p. 59b, abstract #3926, IDS).
Kas-Deleen et al (Clinical and Diagnostic laboratory Immunology, 1998, 5:622-626).
Asahara, et al., (1999).Circ. Res. 85, 221-28.
Asahara, et al., (1997).Science 275, 964-967.
Asahara, et al., (1999).EMBO. J. 18 (14), 3964-72.
Battegay, E. J. (1995).J. Mol. Med. 73, 333-46.
Breier, et al., (1992).Development 114, 521-32.
Connolly, et al., (1989)J. Biol. Chem. 264:20017-24.
Cullinan-Bove, et al., (1993)Endocrinology133:829-37.
Drake, et al., (1998).Ann N. Y. Acad. Sci. 857, 155-79.
Fan, et al., (1995)Trends Pharmacol. Sci. 16:57-66.
Ferrara, (1995)Breast Cancer Research and Treatment36, 127-37.
Folkman, (1990)J. Natl. Cancer Inst. 82:4-6.
Folkman, (1995)Nature Medicine1:27-31.
Folkman, (1995)New England J. of Med. 333:1757-63.
Folkman, (1995)Mol. Med. 1:120-22.
Folkman, (1996)Scientific American275:150-54.
Folkman, (1992)Semin. Cancer Biol. 3:65-71.
Folkman and D'Amore, (1996)Cell87:1153-55.
Frank, et al., (1995)J. Biol. Chem. 270:12607-13.
Jakeman, et al., (1993)Endocrinology, 133:848-59.
Joki, et al., (2001)Nat. Biotechnol. 19:35-39.
Kenyon, et al., (1996)Invest. Ophthalmol. Vis. Sci. 37:1625-32.
Kim, et al., (1993)Nature362:841-44.
King and Brownlee, (1996)Endocrinol. Metab. Clin. North Am. 25:255-70.
Kolch, et al., (1995)Breast Cancer Research and Treatment, 36:139-55.
Nguyen, et al., (1994)Microvasc. Res. 47:31-40.
O'Reilly, et al., (1997)Cell88:277-85.
O'Reilly, et al., (1994)Cell79:315-28.
Rivard and Isner, (1998)Mol. Med. 4:429-40.
Senger, et al., (1993)Cancer and Metastasis Reviews12:303-24.
Shi, et al., (1998)Blood92:362-27.
Shweiki, et al., (1993)J. Clin. Invest. 91:2235-43.
Takahashi, et al., (1999)Nat. Med. 5:434-48.
Weidner, et al., (1991)New England J. of Med. 324:1-8.
Weidner, N., (1995)Amer. J. Path. 147:9-19.
Yancopoulos, et al., (1998)Cell93:661-64.
Ito, H., et al. (1999)Cancer Research, 59, 5875-5877.
Asahara, T., et al. (1999)Circ Res., 85, 221-228.
Asahara, T., et al. (1997)Science, vol. 275, 964-967.
Isner, J.M., et al. (1999)The Journal of Clinical Investigation, vol. 103, No. 9, 1231-1236.
Mancuso, P. et al., “Resting and activated endothelial cells are increased in the peripheral blood of cancer patients.” Blood 97(11):3658-3661, 2001.
Mancuso, P, et al., “Resting and activated endothelial cells are increased in the peripheral blood of cancer patients.” Abstract, Blood 96(11):59b, 2000.
Rafii, S., “Circulating endothelial precursors: mystery, reality, and promise.” J Clin Invest 105(1):17-19, 2000.
Monestiroli, S. et al., “Kinetics and Viability of Circulating Endothelial Cells As Surrogate Angiogenesis Marker in an Animal Model of Human Lymphoma.” Cancer Res 61:4341-4344, 2001.
Eder, J.P. et al., “Recombinant Human Endostatin: Results of a Phase I Clinical Trial.” Presented in Amsterdam, American Association of Cancer Research, Nov. 7, 2000.
Atala Anthony
Schuch Gunter
Soker Shay
Children's Medical Center Corporation
Goddard Laura B
Nixon & Peabody LLP
LandOfFree
Methods for assessing antiangiogenic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for assessing antiangiogenic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for assessing antiangiogenic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4166694